U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.

Shares of Incyte Corporation (NASDAQ:INCY) fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.

Incyte shares dipped 15.3% to $57.50 in the pre-market trading session.

Here are some other stocks moving lower in pre-market trading.

Now Read This:

• IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying

Photo: Shutterstock